Skip to content
value.today

Vivex Biomedical, Inc.

🇺🇸 Marietta, Georgia, USABiotechnologyFounded 2012
Total raised
$20 M
3 rounds on record
Latest round
$6 M
Jan 2017
First round on record
Jul 2013
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vivex Biomedical, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2017$6 MNo. 3$2 to $10 million

Vivex Biomedical, Inc.: Raise no. 3, Jan 2017

Investors in this round

38 investors had bought by the notice of May 11, 2017: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $7 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dr. H Thomas Temple · Executive Officer · Chief Medical Officer
  • Holly S. Mason · Executive Officer
  • Stuart J Komenski · Executive Officer · Chief Financial Officer
  • Timothy Thomas Ganey, Ph.D. · Executive Officer · Chief Scientific Officer
  • Tracy S. Anderson · Executive Officer, Director · President and Chief Executive Officer
  • Barry Thomas Salzman · Director · Executive Chairman of Board of Directors
  • J. Miguel Fernandez de Castro · Director
  • James K. Price · Director
  • John A. McCallum · Director
  • Richard E. Perlman · Director
  • Timothy S. Taylor · Director · Chairman of Board of Directors
  • U. Bertram Ellis, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tracy S. Anderson, Chief Executive Officer. Source: SEC Form D, newest notice filed May 11, 2017. Read the notice at the SEC.

equitySEC
Dec 2015$7 MNo. 2$2 to $10 million

Vivex Biomedical, Inc.: Raise no. 2, Dec 2015

Investors in this round

42 investors had bought by the notice of Jan 5, 2016: 42 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $10 M offered; $3 M still to sell
Smallest investment taken
$379
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dr. H. Thomas Temple · Executive Officer · Chief Medical Officer
  • Holly S. Mason · Executive Officer · Vice President of Marketing
  • Ricardo J. Nunez · Executive Officer · General Counsel and Corporate Secretary
  • Thomas J. Gibson · Executive Officer · Chief Financial Officer
  • Timothy J. Ganey, Ph.D. · Executive Officer · Chief Scientific Officer
  • Tracy S. Anderson · Executive Officer, Director · President and Chief Executive Officer
  • Barry J. Salzman · Director · Executive Chairman of Board of Directors
  • J. Miguel Fernandez de Castro · Director
  • James K. Price · Director
  • Jeffrey A. Smith · Director
  • John A. McCallum · Director
  • Richard E. Perlman · Director
  • Timothy J. Taylor · Director · Chairman of Board of Directors
  • U. Bertram Ellis, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series A Convertible Preferred Stock”

Signed by Ricardo J. Nunez, Corporate Secretary. Source: SEC Form D, newest notice filed Jan 5, 2016. Read the notice at the SEC.

equitySEC
Jul 2013$7 MNo. 1$2 to $10 million

Vivex Biomedical, Inc.: Raise no. 1, Jul 2013

Investors in this round

51 investors had bought by the notice of Sep 16, 2013: 51 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
$100,000
Paid to its own people
$300,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Georgia

People named in the notice

  • Holly Mason · Executive Officer
  • John Marsh · Executive Officer
  • Michael Rozmajzl · Executive Officer
  • Tracy Anderson · Executive Officer, Director
  • David R. Greenberg · Director
  • H. Thomas Temple · Director
  • Jeffrey A. Smith · Director
  • John Bertram McCallum · Director
  • Jouko R. Rissanen · Director
  • Saadiq Thomas El-Amin, III · Director
  • Thomas A. Greene · Director
  • Timothy Lusby · Director
  • Timothy Taylor · Director
  • U. Bertram Ellis, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Estimated consulting fees subject to future engagement of consultant.”
  • On the amounts: “SERIES A PREFERRED STOCK”

Signed by Blake Stone, Assistant General Counsel. Source: SEC Form D and 1 amendment, newest notice filed Sep 16, 2013. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vivex Biomedical, Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (May 2017).

    SEC Form D (revenue range) · May 2017

  • Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2013; revenue between $25 million and $100 million in 2016; revenue between $25 million and $100 million in 2017.

    SEC Form D (revenue range) · May 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2017

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Vivex Biomedical, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 51 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vivex Biomedical, Inc.
NameRoleNamed in
Dr. H Thomas TempleChief Medical OfficerMay 2017
Holly S. MasonExecutive officerMay 2017
Stuart J KomenskiChief Financial OfficerMay 2017
Timothy Thomas Ganey, Ph.D.Chief Scientific OfficerMay 2017
Tracy S. AndersonPresident and Chief Executive OfficerMay 2017
Dr. H. Thomas TempleChief Medical OfficerJan 2016
Ricardo J. NunezGeneral Counsel and Corporate SecretaryJan 2016
Thomas J. GibsonChief Financial OfficerJan 2016
Timothy J. Ganey, Ph.D.Chief Scientific OfficerJan 2016
Holly MasonExecutive officerSep 2013
John MarshExecutive officerSep 2013
Michael RozmajzlExecutive officerSep 2013
Tracy AndersonExecutive officerSep 2013
Barry Thomas SalzmanExecutive Chairman of Board of DirectorsMay 2017
J. Miguel Fernandez de CastroDirectorMay 2017
James K. PriceDirectorMay 2017
John A. McCallumDirectorMay 2017
Richard E. PerlmanDirectorMay 2017
Timothy S. TaylorChairman of Board of DirectorsMay 2017
Tracy S. AndersonPresident and Chief Executive OfficerMay 2017
U. Bertram Ellis, Jr.DirectorMay 2017
Barry J. SalzmanExecutive Chairman of Board of DirectorsJan 2016
Jeffrey A. SmithDirectorJan 2016
Timothy J. TaylorChairman of Board of DirectorsJan 2016
David R. GreenbergDirectorSep 2013
H. Thomas TempleDirectorSep 2013
John Bertram McCallumDirectorSep 2013
Jouko R. RissanenDirectorSep 2013
Saadiq Thomas El-Amin, IIIDirectorSep 2013
Thomas A. GreeneDirectorSep 2013
Timothy LusbyDirectorSep 2013
Timothy TaylorDirectorSep 2013
Tracy AndersonDirectorSep 2013